3-6-06

Express Mail Label No.: EV 695510657 US

Date of Deposit: March 2, 2006

Attorney Docket No.: 23239-531 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANTS:

Stanton et al.

RIAL NUMBER:

10/826,077

EXAMINER:

Not Yet Assigned

FILING DATE:

April 15, 2004

ART UNIT:

1635

For:

APTAMER-TOXIN MOLECULES AND METHODS FOR USING

SAME

Mail Stop Amendment

2

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (1 page), in duplicate; and
- 3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23239-531 CIP. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

or R. Elrifi, Reg. No. 39,529

Jennifer A. Karnakis, Reg. No. 53,097

Attorneys for Applicants c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Customer No. 30623

Date: March 2, 2006

Express Mail Label No.: EV 695510657 US

Date of Deposit: March 2, 2006 Attorney Docket No.: 23239-531 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANTS:

Stanton et al.

ERIAL NUMBER:

10/826,077

EXAMINER:

Jon Benjamin Ashen

FILING DATE:

April 15, 2004

ART UNIT:

1635

For:

APTAMER-TOXIN MOLECULES AND METHODS FOR USING

SAME

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the Supplementary European Office Search Report for EP 03 76 0481, mailed December 28, 2005, which is related to the above-identified case. Accordingly, no fee or certification is believed required. Copies of the references are not provided as they were previously cited and/or submitted to the USPTO in prior applications, Serial No. 10/600,007, filed June 18, 2003 and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the

APPLICANTS:

Stanton et al.

U.S.S.N.:

10/826,077

information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23239-531 CIP.

Respectfully submitted,

or R. Elrifi, Reg. No. 39,529

Sennifer A. Karnakis, Reg. No. 53,097

Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623 Tel: (617) 542-6000


Fax: (617) 542-2241

Date: March 2, 2006

TRA 2125449v.1

Express Mail Label: EV 695510657 US

Date of Deposit: March 2, 2006





Page 1 of 1 Attorney Docket No.: 23239-531 CIP

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)						Application Numb	10/826,077						
						Filing Date	April 15	April 15, 2004 Stanton					
						First Named Inve	Stanton						
						Group Art Unit		1635 Jon Benjamin Ashen					
						Examiner Name							
						Attorney Docket N	23239-531 CIP						
The state of the s			er de la companya de La companya de la co	U.S.	. P	ATENT DOCUMENT	\$		- 144 - 148		ş		
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	e Na	Name of Patentee(s) or Appli		pplicant(s)	Class	Sub Class	Filing Date If Appropriate			
G - straprogram (2,						7. 2. — Same to — Sympholic and	Size to any photos and a side Side gray .			<u> </u>			
Exam					D APPLICATION DO e of Patentee(s) or A	Class	Sub	Fili	Filing Date				
Initials	No.	Application No.	Date			The contraction of Application (c)		0.000	Class	If Appropriate			
Ž. Ž		A Section Control of the Control of	100 - 100 -	FOREIG	IGN	PATENT DOCUME	NTS						
Exam Initials	Cite Foreign Patent Document Nam No. Office Number			Name	ne of Patentee(s) or Applicant(s)			Date of Publication		Translation Yes No			
74/0 877 2 877 2 877 2 877 2 877 2 877	II.	ОТІ	IER PRIOR	ART - I	NO	N PATENT LITERA	TURE DOCUME	NTS					
Exam Initials	Cite No.	Name of Author Title (when convergists) Dublication Values Decrets Date Pte											
	*C88	Bodev et al. An	Bodey et al. <i>Anticancer Res.</i> , 16:661-674 (1996)										
	*C89	Brody et al. Rev. Mol. Biotechnol., 74:5-13 (2000)											
	*C90	George, D. Sem. Oncol., 28(5 - Supl. 17):27-33 (2001)											
	*C91	Gilliland et al. <i>Proc. Natl. Acad. Sci. USA</i> , 77(8):4539-4543 (1980)											
	*C92	Jayasema, S. Clin. Chem., 45(9):1628-1650 (1999)											
	*C93	Lavrovsky et al. Biochem. Mol. Med., 62:11-22 (1997)											
	*C94	Pastan et al. Science, 254:1173-1177 (1991)											
	*C95	Pietras et al. Cancer Res., 61(7):2929-2934 (2000)											
	*C96	Pirker, R. J. Cancer Res. Clin. Oncol., 114(4):385-393 (1988)											
	*C97	Siegall, C. Cancer, 74(3):1006-1012 (1994)											
	*C98	Waldmann, T. Science, 252:1657-1661				661 (1991)							
*C99 Supplementary European Search Report for EP 03 76 0481, mailed December 28, 200									28, 2005	•			
* A copy o 10/600,00 divisional	7, filed	ference is not provided June 18, 2003, and relions).	as it was p ied upon for	reviously r an earli	ly c	ited by or submitted t filing date under 35 L	to the office in a J.S.C. §120 (cor	prior applica	ition, Seria entinuation	al No. i-in-part, a	and		
Examine Signatur						Date Considered							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.